South African Tuberculosis Vaccine Initiative (SATVI)
- Company typePrivate
- Founded2001
- HeadquartersCape Town, South Africa
- Headcount51–100
- GTM typeB2B
- OfferingServices
South African Tuberculosis Vaccine Initiative (SATVI) firmographics
Firmographics- Name
- South African Tuberculosis Vaccine Initiative (SATVI)
- Legal name
- South African Tuberculosis Vaccine Initiative (SATVI)
- Website
- https://satvi.uct.ac.za
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
South African Tuberculosis Vaccine Initiative (SATVI) industry classification
Industry- Product category
- Tuberculosis Vaccine Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Tuberculosis & Mycobacterial Diseases (HLAKAGAH)
- akta.pro secondary industries
- Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE)
Keywords
Where South African Tuberculosis Vaccine Initiative (SATVI) is headquartered
LocationHeadquarters
- HQ city
- Cape Town
- HQ country
- South Africa
- HQ region
- Africa
Offices1 record
Markets served
South African Tuberculosis Vaccine Initiative (SATVI) business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Research Grants and Funding: SATVI operates as an academic research organization funded through grants from international research funders including Wellcome Leap and other global health organizations. Revenue is generated through competitive research grant funding rather than commercial product sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
South African Tuberculosis Vaccine Initiative (SATVI) product offering
Product offeringCore offering
SATVI designs and conducts clinical trials of new tuberculosis vaccine candidates and performs epidemiological studies in TB-endemic communities in the Western Cape, South Africa. It also delivers postdoctoral and postgraduate training in TB immunology, vaccinology, and clinical trial methods, supported by integrated immunology and immunopathology laboratories.
Product overview
SATVI is a research-focused organization (not a product company) operating as a unit within the University of Cape Town's Faculty of Health Sciences. Its offerings consist of tuberculosis vaccine clinical trials research, epidemiological studies, postgraduate research training, immunopathology studies, and community engagement programs. The organization conducts Phase 1b/2a clinical trials of novel TB vaccine candidates and publishes scientific research to advance global TB vaccine development.
Differentiator
Problem solved
Functional benefit
Products and services
- TB vaccine clinical trials Design and conduct of clinical trials of new tuberculosis vaccine candidates in high-burden TB settings, delivered for global vaccine developers and sponsors.
- MTBVAC TB vaccine clinical trial (SATVI site) Clinical trial of the MTBVAC tuberculosis vaccine candidate conducted at SATVI's Western Cape trial site for the sponsoring developer.
- Titan Vaccine Research Project participation SATVI's contribution to the Wellcome Leap Titan Vaccine Research Project, supporting accelerated development of tuberculosis vaccine candidates.
- TB epidemiological studies Epidemiological studies of tuberculosis transmission and disease in TB-endemic communities in the Western Cape, South Africa.
- TB immunology and immunopathology research Immunology and immunopathology research examining TB immune responses, including lymph node sampling, supporting clinical trial endpoints and mechanistic understanding.
- Postgraduate training in vaccinology and immunology Postdoctoral and postgraduate training program in TB vaccinology, immunology, and clinical trial methods offered through the University of Cape Town.
Quantifiable outcome
- MTBVAC vaccine candidate demonstrated similar or stronger immune responses compared to BCG vaccine in adults with comparable safety profile
- +1 more outcomes
Companies that use South African Tuberculosis Vaccine Initiative (SATVI)
Customer profileSegments1 record
Ideal customer profiles3 records
South African Tuberculosis Vaccine Initiative (SATVI) technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
South African Tuberculosis Vaccine Initiative (SATVI) partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- United Nations / WHO (UNHLM on TB)coreProfessor Mark Hatherill addressed the UN High-level Meeting on Tuberculosis advocating for increased investment in TB vaccine R&D. This engagement shapes global TB policy and funding priorities.
- IAVI (A-050 Study)coreCollaboration on the IAVI A-050 study evaluating MTBVAC vaccine candidate. Research findings published in Lancet Global Health demonstrating vaccine safety and immunogenicity in adults compared to BCG.
- UCT Lung InstitutecoreJoint hosting of African parliamentarian delegations and global health representatives for TB research site visits. Co-location of operations at UCT Faculty of Health Sciences campus.
- African Parliamentarians and Global Health RepresentativesminorDelegation of African parliamentarians visited SATVI on 15 May 2026 to witness cutting-edge TB research, building regional capacity and awareness for TB vaccine development.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
South African Tuberculosis Vaccine Initiative (SATVI) competitors and assessment
Company assessmentDirect peers
- Max Planck Institute for Infection Biology: Research institute with deep TB immunology and vaccine development programs, including MTBVAC co-development history. Comparable in advanced TB vaccine science and translational research focus.
- TuBerculosis Vaccine Initiative (TBVI): European-based TB vaccine research and development coordination body. Funds and coordinates TB vaccine candidates through discovery, preclinical, and clinical stages, overlapping directly with SATVI's translational research focus.
- National Institute for Research in Tuberculosis (NIRT): Indian Council of Medical Research institute focused on TB clinical trials, immunology, and epidemiology. Runs Phase 1-3 TB vaccine trials in a high-burden country setting analogous to SATVI's role in South Africa.
- IAVI: International AIDS Vaccine Initiative has expanded into TB vaccine development and is SATVI's direct co-development partner on the MTBVAC A-050 study. Operates a similar clinical trials model for infectious disease vaccines in low- and middle-income countries.
- Aeras (now part of IAVI): Former standalone TB vaccine product development partnership, now merged with IAVI. Historically ran TB vaccine clinical trials across multiple high-burden African and Asian sites, directly comparable to SATVI's clinical operations model.
- TuBerculosis Research Centre (ICMR-TRC), Chennai: India's premier TB research institution conducting clinical trials and epidemiological studies for TB vaccines and diagnostics. Comparable in mission (TB clinical research in a high-burden country) and academic institutional setting.
Emerging players
- Texas Biomedical Research Institute: Independent biomedical research institute with significant TB and infectious disease vaccine research programs including BSL-3 capabilities. Comparable in academic translational research model for infectious disease vaccines.
- Harvard Medical School Center for Global Health Delivery: Academic research center conducting TB epidemiology and vaccine-related research with global field sites. Comparable in academic research model and TB focus, though broader in scope than SATVI's vaccine specialization.
- London School of Hygiene & Tropical Medicine TB Centre: Leading UK academic center with active TB vaccine epidemiology and clinical research programs in Africa and Asia. Comparable academic translational research model and TB vaccine pipeline involvement.
Regional players
- Wellcome Centre for Infectious Disease Research in Africa (CIDRI-Africa): Wellcome-funded infectious disease research center based at the University of Cape Town, with overlapping institutional affiliation with SATVI. Comparable in Africa-based clinical research operations and Wellcome grant model, though broader in pathogen scope.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
South African Tuberculosis Vaccine Initiative (SATVI) social profiles
Digital presenceSouth African Tuberculosis Vaccine Initiative (SATVI) financial estimates
Financial estimateRevenue estimate
Valuation estimate
South African Tuberculosis Vaccine Initiative (SATVI) leadership team
Management profileNumber of profiles
Profiles6 records
South African Tuberculosis Vaccine Initiative (SATVI) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
South African Tuberculosis Vaccine Initiative (SATVI) M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about South African Tuberculosis Vaccine Initiative (SATVI)
What does South African Tuberculosis Vaccine Initiative (SATVI) do?
SATVI designs and conducts clinical trials of new tuberculosis vaccine candidates and performs epidemiological studies in TB-endemic communities in the Western Cape, South Africa. It also delivers postdoctoral and postgraduate training in TB immunology, vaccinology, and clinical trial methods, supported by integrated immunology and immunopathology laboratories.
Is South African Tuberculosis Vaccine Initiative (SATVI) a public or private company?
South African Tuberculosis Vaccine Initiative (SATVI) is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was South African Tuberculosis Vaccine Initiative (SATVI) founded?
South African Tuberculosis Vaccine Initiative (SATVI) was founded in 2001. It employs 51 to 100 people.
Where is South African Tuberculosis Vaccine Initiative (SATVI) based?
South African Tuberculosis Vaccine Initiative (SATVI) is headquartered in Cape Town, South Africa, in the Africa region.
How does South African Tuberculosis Vaccine Initiative (SATVI) make money?
One revenue line is on record: research Grants and Funding.
Who are South African Tuberculosis Vaccine Initiative (SATVI)'s main competitors?
Direct peers on record are Max Planck Institute for Infection Biology, TuBerculosis Vaccine Initiative (TBVI), National Institute for Research in Tuberculosis (NIRT), IAVI, Aeras (now part of IAVI) and TuBerculosis Research Centre (ICMR-TRC), Chennai. Emerging players are Texas Biomedical Research Institute, Harvard Medical School Center for Global Health Delivery and London School of Hygiene & Tropical Medicine TB Centre. Wellcome Centre for Infectious Disease Research in Africa (CIDRI-Africa) is listed as a regional player.
Does South African Tuberculosis Vaccine Initiative (SATVI) have an API?
No public API is recorded for South African Tuberculosis Vaccine Initiative (SATVI).
What industry is South African Tuberculosis Vaccine Initiative (SATVI) in?
South African Tuberculosis Vaccine Initiative (SATVI)'s product category is Tuberculosis Vaccine Research. Its primary akta.pro industry code is HLAKAGAH, Tuberculosis & Mycobacterial Diseases, with a secondary code of HLAIAEAM, Vaccine Clinical Development & Regulatory Affairs. Its NAICS code is 541714 and its SIC code is 8731.